Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Delignat

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Thrombosis and Haemostasis : JTH|October 1, 2014
Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia AB Gangadharan, S Delignat, V Ollivier, et al.
Journal of Thrombosis and Haemostasis : JTH|January 22, 2011
Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cellsY Meslier, S André, J D Dimitrov, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 5, 2014
Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A miceI Peyron, J D Dimitrov, S Delignat, et al.
Chemotherapy|September 19, 2001
Variable sensitivity of lymphoblastoid cells to apoptosis induced by Viscum album Qu FrF, a therapeutic preparation of mistletoe lectinJ P Duong Van Huyen, Sooryanarayana, S Delignat, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 31, 2013
Predictive immunogenicity of Refacto AFS Delignat, Y Repessé, L Gilardin, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|June 12, 2003
Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseasesJ Bayry, N Misra, V Latry, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 5, 2003
Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseasesJ Bayry, M Thirion, N Misra, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 3, 2011
Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia AS Delignat, Y Repessé, A-M Navarrete, et al.
Journal of Thrombosis and Haemostasis : JTH|August 18, 2009
Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia AA Navarrete, S Dasgupta, S Delignat, et al.
Journal of Thrombosis and Haemostasis : JTH|April 5, 2012
Heme binds to factor VIII and inhibits its interaction with activated factor IXY Repessé, J D Dimitrov, I Peyron, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Thrombosis and Haemostasis : JTH|October 1, 2014
Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia AB Gangadharan, S Delignat, V Ollivier, et al.
Journal of Thrombosis and Haemostasis : JTH|January 22, 2011
Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cellsY Meslier, S André, J D Dimitrov, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 5, 2014
Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A miceI Peyron, J D Dimitrov, S Delignat, et al.
Chemotherapy|September 19, 2001
Variable sensitivity of lymphoblastoid cells to apoptosis induced by Viscum album Qu FrF, a therapeutic preparation of mistletoe lectinJ P Duong Van Huyen, Sooryanarayana, S Delignat, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 31, 2013
Predictive immunogenicity of Refacto AFS Delignat, Y Repessé, L Gilardin, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|June 12, 2003
Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseasesJ Bayry, N Misra, V Latry, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 5, 2003
Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseasesJ Bayry, M Thirion, N Misra, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 3, 2011
Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia AS Delignat, Y Repessé, A-M Navarrete, et al.
Journal of Thrombosis and Haemostasis : JTH|August 18, 2009
Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia AA Navarrete, S Dasgupta, S Delignat, et al.
Journal of Thrombosis and Haemostasis : JTH|April 5, 2012
Heme binds to factor VIII and inhibits its interaction with activated factor IXY Repessé, J D Dimitrov, I Peyron, et al.
Pageof 2